Will This Beaten-Down Stock Bounce Back? 3 Things to Know
Vertex Pharmaceuticals (NASDAQ: VRTX) has given more than one investor a headache over the past year. The company's shares have suffered ever since the company announced the failure of two candidates -- one in October 2020 and one this spring -- in clinical trials. They've dropped more than 30% since the first failure. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments.
Considering the time Vertex shares have spent in the doldrums, you may be getting a little impatient. In fact, you may be wondering: Will this beaten-down stock ever will recover? Before answering, here are three things to know.
Image source: Getty Images.
Source Fool.com
